New Pill for Hard-to-Control High Blood Pressure

Baxfendy (baxdrostat) is a highly selective oral aldosterone synthase inhibitor. Aldosterone promotes sodium and water retention, raises blood volume, and contributes to high blood pressure; inhibiting the enzyme that makes aldosterone lowers plasma aldosterone and blood pressure. Older mineralocorticoid receptor antagonists (MRAs) block the hormone’s receptor; this medicine reduces production of the hormone itself. It is the first FDA-approved aldosterone synthase inhibitor.

The FDA approved it under NDA 219878 on 15 May 2026 (FDA Novel Drug Approvals for 2026 table; NDA approval letter; DailyMed marketing start 05/15/2026; Initial U.S. Approval: 2026 on the USPI). The holder / packager on DailyMed is AstraZeneca Pharmaceuticals LP (applicant on the clinical review: AstraZeneca AB). Priority Review applied (clinical review / PDUFA goal 17 May 2026; review completion 15 May 2026).

The labelled indication is narrow and clear: in combination with other antihypertensive drugs, for the treatment of hypertension, to lower blood pressure in adults who are not adequately controlled on other agents. The USPI’s standard antihypertensive preamble notes that lowering blood pressure reduces fatal and nonfatal cardiovascular events (mainly strokes and myocardial infarctions) across drug classes — and that there are no controlled trials demonstrating risk reduction of these events with Baxfendy. Talk about blood-pressure lowering on this product, not a Baxfendy-specific stroke or heart-attack outcomes claim.

Where this is taking place

Pivotal hypertension trials that support the US label are completed. The commercial door is a US prescription, not a trial slot.

United States — commercial labelled door. Cardiology, hypertension clinic, nephrology, or primary care experienced in resistant / uncontrolled hypertension writes a 1 mg or 2 mg once-daily prescription under the USPI. Prior authorization and plan coverage still apply. Authorized ≠ funded.

BaxHTN — NCT06034743 — Phase 3, COMPLETED. Lead sponsor: AstraZeneca. Actual enrollment 796 on ClinicalTrials.gov (USPI analysis: 794 treated). Adults with seated systolic blood pressure ≥140 and <170 mmHg on ≥2 antihypertensives including a diuretic (uncontrolled) or ≥3 including a diuretic (resistant), eGFR ≥45 mL/min/1.73 m², serum potassium ≥3.5 and <5.0 mEq/L. After a 2-week placebo run-in, patients with SBP ≥135 mmHg were randomized 1:1:1 to baxdrostat 1 mg, 2 mg, or placebo once daily for 12 weeks. Primary: change in seated office SBP at Week 12. CT.gov: start 22 Nov 2023; primary completion 21 May 2025; completion 10 Oct 2025; hasExpandedAccess: false. Completed — not an enrolment path.

Bax24 — NCT06168409 — Phase 3 ambulatory BP trial in resistant hypertension, cited in the USPI pooled safety set and published in The Lancet. Supportive / safety evidence for the programme; the USPI’s pivotal efficacy table for labelling is BaxHTN. Completed — not an enrolment path.

BrigHTN — NCT04519658 — Phase 2 dose-ranging trial in resistant hypertension (also in the USPI safety pool). Historical dose-finding. Not the commercial start path.

European Union. EMA granted a product-specific paediatric waiver for treatment of hypertension (EMEA-003507-PIP01-23, decision P/0527/2023, 29 Dec 2023). A separate waiver exists for primary aldosteronism (EMA/PE/0000227014, 14 Apr 2025). Waiver ≠ European Commission marketing authorisation. No EC MA / SmPC retrieved for this draft.

Canada. SUR row for Baxdrostat (class month 2026-06, AstraZeneca Canada Inc, new active substance). No retrieved NOC or DIN. Trial geography on multinational studies ≠ a Canadian licence.

Approval matrix

Access by country

• United States: Ask the clinician who already manages your blood pressure (cardiology, hypertension clinic, nephrology, or experienced primary care). FDA-labelled 15 May 2026 for adults needing add-on therapy when BP is not adequately controlled on other agents. Dose: 2 mg once daily (or 1 mg if your clinician judges higher hyperkalemia / hyponatremia risk). With or without food; swallow whole. Labs for potassium and sodium before start and periodically. AstraZeneca adverse-event / product contact on the USPI / Patient Information: 1-800-236-9933; MedWatch 1-800-FDA-1088. DailyMed / Drugs@FDA host the label. No copay dollars here. Prior authorization still applies. Children not established. Do not treat this as a proven Baxfendy-specific stroke/MI reduction claim beyond BP lowering.

• Canada (zoom): Not authorised on sources checked (no NOC/DIN). SUR lists Baxdrostat (2026-06 class month, AstraZeneca Canada Inc, new active substance) — that is review in progress, not a Product Monograph you can fill. Provincial / territorial / NIHB funding is N/A until there is a NOC. Special Access Programme supply: unknown / not confirmed. Do not mail-order a US bottle as a Canadian care plan.

• European Union: Paediatric waiver only on sources checked. No EC marketing authorisation retrieved. Wait for an EC decision and a published SmPC before treating an EU pack as real. Do not DIY-import.

• United Kingdom / Australia / Japan / China / Switzerland: Authorisation unknown / not confirmed. Trial sites ≠ licence. Specialist + local named-patient / special-access only if those programs actually apply in writing — not invented here.

If your regulator has not authorised it: do not import on your own.

Who is eligible (from the US label)

United States (USPI / DailyMed):

• Adult (18+).
• Hypertension not adequately controlled on other agents.
• Use in combination with other antihypertensive drugs to lower blood pressure.
• Recommended dose: 2 mg orally once daily; 1 mg once daily if increased risk of hyperkalemia or hyponatremia.
• Pivotal BaxHTN population (for context, not a hard label checklist): seated SBP ≥140 to <170 mmHg; ≥2 antihypertensives including a diuretic (or ≥3 including a diuretic for the resistant subgroup); eGFR ≥45; potassium ≥3.5 and <5.0 mEq/L at entry; simultaneous ACEi plus ARB, and MRA / potassium-sparing diuretic use, were not allowed in the trial design described on the label.
• Assess and correct serum potassium and sodium before starting; monitor periodically (more often if older, diabetes, CKD, or on drugs that raise potassium).
• Pediatrics: safety and effectiveness not established.
• Geriatrics: no dose adjustment by age alone; hyperkalemia more common at ≥65 (and higher still at ≥75 on 2 mg in BaxHTN per USPI).
• Renal: safety/effectiveness when initiated at eGFR <45 not established; no dosage adjustment required solely for eGFR ≥45 unless hyperkalemia risk.
• Pregnancy: human data insufficient; report pregnancies to AstraZeneca 1-800-236-9933. Hypertension in pregnancy needs careful monitoring.
• Lactation: unknown in human milk; baxdrostat transfers to milk in rats; discuss feeding plan.
• Contraindications: none.
• Not a Baxfendy-specific MACE indication. BP lowering is the labelled effect.

Canada / EU / other: no retrieved national Product Monograph / SmPC to quote for eligibility. Outside the US, start with whether a regulator has authorised the product at all.

What the pivotal studies showed (label vs journal)

Use the USPI for a US prescription conversation. Journals are supportive reading; small number differences are rounding / analysis choices.

BaxHTN (NCT06034743) — USPI primary numbers

• n=794 treated (1 mg 264 / 2 mg 266 / placebo 264 in the NEJM report; USPI efficacy table n≈266 / 264 / 263 for SBP). Mean baseline SBP ~149 mmHg; mean age 61; ~41% on three background antihypertensives; all on a diuretic; ~90% on ACEi or ARB.
• Primary (USPI Table 2, Week 12 seated SBP): mean change −15.7 mmHg (2 mg), −14.5 (1 mg), −5.8 (placebo). Difference vs placebo: −9.8 mmHg (95% CI −12.6, −7.0; p<0.0001) for 2 mg; −8.7 mmHg (95% CI −11.5, −5.8; p<0.0001) for 1 mg.
• Diastolic BP also improved vs placebo (USPI): difference −3.9 mmHg (2 mg) and −3.3 mmHg (1 mg).
• Randomized withdrawal (Week 24→32, USPI): continuing 2 mg vs switching to placebo — mean SBP difference −5.1 mmHg (95% CI −8.3, −1.9; p=0.002), supporting maintenance of effect.
• Benefit generally consistent across pre-specified subgroups on the label (age, sex, BMI, eGFR, baseline SBP).

Journal (not the label): Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B; BaxHTN Investigators. N Engl J Med. 2025;393(14):1363-1374. DOI 10.1056/NEJMoa2507109. PMID 40888730. Reports the same Week-12 placebo-corrected SBP differences (−8.7 / −9.8 mmHg) and notes potassium >6.0 mmol/L in 2.3% (1 mg), 3.0% (2 mg), 0.4% (placebo). Not a preprint. Prefer USPI table language in clinic.

Bax24 (NCT06168409) — supportive ambulatory evidence (Lancet; also in USPI safety pool)

• Resistant hypertension; baxdrostat 2 mg vs placebo; primary: 24-hour ambulatory SBP at Week 12.
• Journal: Azizi M, Brown JM, Dwyer JP, Flack JM, et al. Lancet. 2026;407:988-999. DOI 10.1016/S0140-6736(25)02549-8. Placebo-corrected 24-hour ambulatory SBP difference −14.0 mmHg (95% CI −17.2, −10.8; p<0.0001). Not a preprint. The US labelled pivotal efficacy narrative remains BaxHTN seated office SBP.

BrigHTN (NCT04519658) — Phase 2 (safety pool / dose finding)

• Dose-ranging Phase 2 in resistant hypertension; informed 1 mg / 2 mg doses. Cited in USPI pooled safety. Not the primary labelling efficacy table.

How it is taken (US label — keep this exact)

• Recommended dosage: 2 mg orally once daily.
• If increased risk of hyperkalemia or hyponatremia: 1 mg orally once daily.
• Take with or without food.
• Swallow tablets whole. Do not cut, crush, or chew.
• Missed dose: take the next dose at the usual time. Do not take a double dose the same day.
• Strengths: 1 mg (pink, “BX” / “1”) and 2 mg (yellow, “BX” / “2”) film-coated tablets.
• Store 20–25 °C (excursions 15–30 °C) in the original bottle with desiccant; protect from moisture. Common bottle NDCs on DailyMed: 0310-6001-30 (1 mg × 30), 0310-6002-30 (2 mg × 30).
• Before and during treatment: check serum potassium and sodium; correct abnormalities before starting.

Safety (USPI)

• Contraindications: none.
• Warnings: hyperkalemia and hyponatremia — monitor labs; interrupt or discontinue if clinically significant; permanently discontinue if it recurs after restart.
• Most common adverse reaction (more frequent than placebo and ≥5% on Baxfendy): hyperkalemia.
• Pooled 12-week randomized periods (BaxHTN, BrigHTN, Bax24) — reactions ≥2% and greater than placebo (USPI Table 1):

• Lab: potassium >5.5 mEq/L in 12.2% (2 mg), 6.3% (1 mg), 0.9% (placebo). Sodium <130 mEq/L in 3.7% / 3.3% / 0.9%. Mean eGFR fell (~7–8 mL/min/1.73 m² placebo-corrected at Week 12) and rose after stopping — consistent with a hemodynamic effect on the label.
• Hyperkalemia led to permanent discontinuation in 1.8% (2 mg), 0.6% (1 mg), 0% (placebo) in that pool.
• Drug interactions: drugs that raise potassium — monitor K more often; strong/moderate CYP3A inducers — monitor BP effect more often (may lower baxdrostat exposure).
• Pregnancy / lactation / pediatrics: see eligibility.
• Report suspected adverse reactions to AstraZeneca 1-800-236-9933 or FDA MedWatch 1-800-FDA-1088.

No boxed warning on the USPI retrieved for this draft. That is not “no risk” — the main safety story is potassium, sodium, hypotension/dizziness, and lab monitoring.

Research team (source-only)

Names and roles as they appear on primary sources — not a clinic directory.

• AstraZeneca AB / AstraZeneca Pharmaceuticals LP (Wilmington, DE on the USPI) — NDA 219878 applicant / DailyMed packager / distributor. Adverse reactions / Patient Information contact: 1-800-236-9933.
• AstraZeneca — lead sponsor, BaxHTN (NCT06034743), Bax24 (NCT06168409). CT.gov record retrieved for this draft lists no overall officials / central contacts — no named site PI on that API view.
• Anh Ly, MSc — Regulatory Affairs Director, addressee on the NDA approval letter (corporate regulatory contact, not a patient hotline beyond the USPI number).
• John M. Flack, M.D., and coauthors — BaxHTN NEJM paper (Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ESW, Olsson DS, Perl S, Shibata H, Wang JG, Wilderäng U, Wittes J, Williams B; BaxHTN Investigators).
• Bryan Williams — BaxHTN Investigator author on the NEJM paper (company materials have also described him as a primary investigator in trial communications — journal authorship is the source used here).
• Michel Azizi, M.D., and coauthors — Bax24 Lancet paper (Azizi M, Brown JM, Dwyer JP, Flack JM, et al.).
• AstraZeneca AB — EMA PIP / waiver public enquiry contact on the hypertension waiver page: paediatrics@astrazeneca.com, Tel. +46 855324400 (paediatric administrative contact, not a treating clinic).

Site-level clinic phone numbers are not listed on these trial records — ask your own hypertension clinician, not a directory built from this page.

How to talk to a doctor

Bring the brand, the INN, the NCT numbers, and the regulator that applies:

1. “My blood pressure is still high on my current antihypertensives. The FDA labelled Baxfendy (baxdrostat) on 15 May 2026 as an oral aldosterone synthase inhibitor add-on for adults not adequately controlled. Is that a fit for me?”
2. “The USPI recommends 2 mg once daily, or 1 mg if I am at higher risk of high potassium or low sodium. Can we check my potassium, sodium, and eGFR and decide the starting dose?”
3. “BaxHTN (NCT06034743) showed roughly 9–10 mmHg extra seated SBP reduction vs placebo at 12 weeks on the USPI. How will we measure response and what is our BP target?”
4. “I understand this is labelled to lower blood pressure; the label says there are no controlled trials proving stroke/MI reduction specifically with Baxfendy. What outcomes are we aiming for in my case?”
5. “Side effects to watch: hyperkalemia, hyponatremia, low blood pressure, dizziness, muscle spasms. Should I avoid potassium supplements or salt substitutes with potassium?”
6. “I am / am not on an MRA, ACE inhibitor, ARB, or potassium-sparing diuretic. How should we adjust my background regimen if we add Baxfendy?”
7. If Canada / EU / elsewhere: “Is there a licence in this country yet? I understand US approval is not a Canadian DIN or an EU pack, and Canada’s SUR listing is not an NOC. I will not mail-order.”
8. “Prior authorization — what does my plan need (BP logs, current med list, potassium labs)?”

Canada zoom: not authorised (SUR only)

There is no retrieved Health Canada Notice of Compliance or DIN for Baxfendy / baxdrostat on the sources used for this draft. The new-drug SUR page does list Baxdrostat (Antihypertensives; class month 2026-06; AstraZeneca Canada Inc; new active substance). That means a submission is under review — not that a Product Monograph exists, not that pharmacies can dispense a Canadian pack, and not a reason to order a US bottle online. Wait for a real NOC / Product Monograph before treating Canada as labelled.

Bottom line

Baxfendy (baxdrostat) is the first FDA-approved aldosterone synthase inhibitor — 1 mg or 2 mg once daily oral tablets — labelled 15 May 2026 in combination with other antihypertensives to lower blood pressure in adults not adequately controlled on other agents. BaxHTN (NCT06034743) showed about 8.7–9.8 mmHg placebo-adjusted seated SBP reductions at Week 12 on the USPI. Main safety watch: potassium and sodium. Canada is SUR-listed, not authorised; the EU has a paediatric waiver, not an EC licence on sources checked. The practical door in the United States is a hypertension-experienced clinician and a labelled prescription. Completed Phase 3 trials are not enrolment paths.

---

Primary sources

1. DailyMed BAXFENDY (baxdrostat) tablets, setid b1fc1ee7-facc-4099-b3db-a4c1daeaa4be, packager AstraZeneca Pharmaceuticals LP, Revised 5/2026 — https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b1fc1ee7-facc-4099-b3db-a4c1daeaa4be
2. FDA Prescribing Information PDF, NDA 219878, label 219878Orig1s000lbl.pdf — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf
3. FDA NDA approval letter, NDA 219878 — https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf
4. FDA Novel Drug Approvals for 2026 — Baxfendy / baxdrostat / 5/15/2026 — https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
5. FDA clinical review, NDA 219878 (review completion 15 May 2026) — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/219878Orig1s000MedR.pdf
6. ClinicalTrials.gov BaxHTN NCT06034743 — https://clinicaltrials.gov/study/NCT06034743
7. ClinicalTrials.gov Bax24 NCT06168409 — https://clinicaltrials.gov/study/NCT06168409
8. ClinicalTrials.gov BrigHTN NCT04519658 — https://clinicaltrials.gov/study/NCT04519658
9. Flack JM, Azizi M, Brown JM, et al. Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension. N Engl J Med. 2025;393(14):1363-1374. DOI 10.1056/NEJMoa2507109 (journal; not the label; not a preprint)
10. Azizi M, Brown JM, Dwyer JP, et al. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24). Lancet. 2026;407:988-999. DOI 10.1016/S0140-6736(25)02549-8 (journal; not the label; not a preprint)
11. Health Canada — Drug and Health Product Submissions Under Review: New drug submissions under review (row: Baxdrostat; Antihypertensives; 2026-06; AstraZeneca Canada Inc; New active substance) — https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/submissions-under-review/new-drug-submissions-under-review.html
12. EMA paediatric waiver EMEA-003507-PIP01-23, decision P/0527/2023, 29 Dec 2023 (treatment of hypertension) — https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003507-pip01-23
13. EMA decision PDF P/0527/2023 — https://www.ema.europa.eu/en/documents/pip-decision/p-0527-2023-ema-decision-29-december-2023-granting-product-specific-waiver-baxdrostat-emea-003507-pip01-23_en.pdf